K.D. ZOROB¹, L.K. TUMAKOVA¹, D.D. MUKHAMETOVA¹, E.S. BODRYAGINA¹, A.KH. ODINTSOVA², L.R. SADYKOVA², D.I. ABDULGANIEVA^{1, 2}

¹Kazan State Medical University, Kazan

²Republic Clinical Hospital, Kazan

  Contact details:

Zorob K.D. — resident of the Department of Hospital Therapy

Address: 49 Butlerov St., Kazan, Russian Federation, 420012, tel.: +7 (843) 237-32-61, e-mail: kristdm74@gmail.com

Inflammatory bowel diseases (IBD), such as ulcerative colitis (UC) and Crohn’s disease (CD), are autoinflammatory diseases for which basic therapy is not always effective, and some patients may require the use of biological therapy.

The purpose was to evaluate the clinical characteristics of patients with IBD who were on biological therapy.

Material and methods. We included 70 patients with IBD who were treated with biological therapy and were observed at the Republican Clinical Hospital in Kazan. Patients with UC were 41 (58%), with CD — 29 (42%). Mean age in IBD was 37 [28; 42] years old, 43% were female.

Results. 23 (33%) patients with IBD were in remission, 47 (67%) were in exacerbation. Mild UC was observed in 17 (41.4%) cases, moderate — in 11 (26.8%), severe — in 2 cases (4.8%). Mild CD was in 9 (31%) patients, moderate — in 7 (24.1%), severe — in 1 (3.4%). According to the location, total colitis predominated — 30 (74%), in CD terminal ileitis was more common — in 14 (48%) patients. Extraintestinal manifestations were diagnosed in 14 (20%) patients with IBD, complications — in 12 (17%), surgical interventions — in 8 (11%). Among all biological therapy, infliximab was most often used – in 20 (29%) cases, adalimumab — 15 (21%), vedolizumab — 12 (17%); four patients received dual targeted therapy.

Conclusion. Maintaining a register of patients with IBD receiving biological therapy is an effective tool for analyzing the clinical features of UC and CD, as well as the efficacy and the safety of the therapy.

Key words: inflammatory bowel diseases, ulcerative colitis, Crohn’s disease, register, biological therapy.

REFERENCES

1. Ng S.C., Kaplan G.G., Tang W. et al. Population density and risk of infammatory bowel disease: a prospective population-based study in 13 countries or regions in Asia-Pacific. Am. J. Gastroenterol, 2019, vol. 114 (1), pp. 107–115. DOI: 10.1038/s41395-018-0233-2
2. Parigi T.L., D’Amico F., Abreu M.T. et al. Difficult-to-treat inflammatory bowel disease: results from an international consensus meeting. Lancet Gastroenterol. Hepatol, 2023, vol. 8 (9), pp. 853–859. DOI: 10.1016/S2468-1253(23)00154-1
3. Ananthakrishnan A.N., Kaplan G.G., Ng S.C. Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century. Clin. Gastroenterol. Hepatol, 2020, vol. 18, pp. 1252–1260. DOI: 10.1016/j.cgh.2020.01.028
4. Maev I.V., Bakulin I.G., Skalinskaya M.I., Skazyvaeva E.V. Inflammatory diseases intestines: transformation of ideas. Terapevticheskiy arkhiv, 2023, vol. 95, no. 12, pp. 1064–1074 (in Russ.). DOI: 10.26442/00403660.2023.12.202507
5. Belousova E.A., Shelygin Yu.A., Achkasov S.I. et al. Clinical and demographic characteristics and treatment approaches in patients with inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) in RF. First results of the national registry analysis. Koloproktologiya, 2023, vol. 1 (83), pp. 65–82 (in Russ.). DOI: 10.33878/2073-7556-2023-22-1-65-82
6. Hammer T., Langholz E. The epidemiology of inflammatory bowel disease: Balance between East and West? A narrativereview. Dig. Med. Res, 2020, vol. 35 (3), pp. 380–389. DOI: 10.1111/jgh.14872
7. Mak W.Y., Zhao M., Ng S.C. et al. The epidemiology of inflammatory bowel disease: East meets West. J. Gastroenterol. Hepatol, 2020, vol. 35, pp. 380–389. DOI: 10.1111/jgh.14872
8. Rosen M.J., Dhawan A., Saeed S.A. Inflammatory bowel disease in children and adolescents. JAMA Pediatr, 2015, vol. 169 (11), pp. 1053–1060. DOI: 10.1001/jamapediatrics.2015.1982
9. Shelygin Yu.A., Ivashkin V.T., Achkasov S.I. et al. Clinical guidelines. Crohn’s disease (K50), adults. Koloproktologiya, 2023, vol. 3, no. 85, pp. 10–49 (in Russ.). DOI: 10.33878/2073-7556-2023-22-3-10-49
10. Walldorf J., Twarz M., Schober C. [et al.] High frequency of secondary, but not primary ocular manifestations of inflammatory bowel disease in patients treated at a tertiary care center. Eur. J. Gastroenterol. Hepatol, 2018, vol. 30 (12), pp. 1502–1506. DOI: 10.1097/MEG.0000000000001248
11. Karmiris K., Avgerinos A., Tavernaraki A. et al. Prevalence and characteristics of extra-intestinal manifestations in a large cohort of Greek patients with inflammatory bowel disease. J. Crohns. Colitis, 2016, vol. 10 (4), pp. 429–436. DOI: 10.1093/ecco-jcc/jjv232
12. Gordon H., Burisch J., Ellul P. et al. ECCO Guidelines on Extraintestinal Manifestations in Inflammatory Bowel Disease. J. Crohns. Colitis, 2024, vol. 18 (1), pp. 1–37. DOI: 10.1093/ecco-jcc/jjad108
13. Bernstein C.N., Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: A population-based study. Am. J. Gastroenterol, 2006, vol. 101 (1), pp. 110–118. DOI: 10.1111/j.1572-0241.2006.00330
14. Fradet C., Kern J., Atanasov P. et al. Impact of surgery and its complications in ulcerative colitis patients in clinical practice: A systematic literature review of real-world evidence in Europe. Int. J. Surg. Open, 2019, vol. 22, pp. 22–32. DOI: 10.1016/j.ijso.2019.11.01014
15. Taylor K., Gibson P.R. Conventional therapy of ulcerative colitis: Corticosteroids. In D.C. Baumgart (Ed.), crohn’s disease and ulcerative colitis: from epidemiology and immunobiology to a rational diagnostic and therapeutic approach. Springer, 2017, pp. 399–412. DOI: 10.1007/978-3-319-33703-6_39
16. Triantafillidis J.K., Zografos C.G., Konstadoulakis M.M., Papalois A.E. Combination treatment of inflammatory bowel disease: Present status and future perspectives. World J. Gastroenterol, 2024, vol. 30 (15), pp. 2068–2080. DOI: 10.3748/wjg.v30.i15.2068
17. Abdulganieva D.I., Odintsova A.Kh., Mukhametova D.D. et al. Regional registry of Crohn’s disease as a tool for prospective observation of patients. Prakticheskaya meditsina, 2014, no. 4–1 (80), pp. 17–18 (in Russ.).
18. Shelygin Yu.A., Ivashkin V.T., Belousova E.A. et alClinical guidelines. Ulcerative colitis (K51), adults. Koloproktologiya, 2023, vol. 22 (1), pp. 10–44 (in Russ.). DOI: 10.33878/2073-7556-2023-22-1-10-44
19. Wewer M.D., Arp L., Sarikaya M. et al. The use and efficacy of biological therapies for inflammatory bowel disease in a danish tertiary centre 2010-2020. Crohns. Colitis 360, 2022, vol. 4 (4), otac041. DOI: 10.1093/crocol/otac041
20. Ahmed W., Galati J., Kumar A. et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol, 2022, vol. 20 (3), pp. 361–379. DOI: 10.1016/j.cgh.2021.03.034